Artelo Biosciences

54 articles with Artelo Biosciences

• Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/8/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, President and Chief Executive Officer of Artelo Biosciences, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

• Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines

  8/4/2021

  Artelo Biosciences, Inc.  today announced the publication of study results in Medical Cannabis and Cannabinoids, a peer-reviewed journal.

• Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021

  7/21/2021

  Artelo Biosciences, Inc. today announced that Ladenburg Thalmann & Co. Inc. will host an R&D showcase focused on the Phase 1b/2a Cancer Appetite Recovery Study (“CAReS”), evaluating the Company’s lead drug candidate, ART27.13.

• Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update

  7/12/2021

  Enrollment in CAReS Study in patients with cancer anorexia on track to deliver first data readout by calendar year-end $10.0 Million of Cash and Cash Equivalents as of May 31, 2021

• Artelo Biosciences to Present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14th

  7/7/2021

  Artelo Biosciences, Inc. today announced that management will be presenting and hosting 1x1 meetings during the Ladenburg Thalmann Healthcare Conference taking place virtually July 13-14, 2021.

• Artelo Biosciences Announces Two Poster Presentations Featured at the 31st Annual ICRS Symposium

  6/22/2021

  Dr. Andrew Yates to Present Poster on the Company’s ART27.13 Cancer Appetite Recovery Study Prof. Saoirse O’Sullivan to Present Poster Related to Artelo’s ART12.11

• Artelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th

  6/2/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021.

• Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update

  4/13/2021

  Recently Commenced Patient Enrollment in Phase 1/2 CAReS Study of ART27.13 in the UK Reported Positive Pre-Clinical Data Associated with Artelo’s Proprietary CBD Cocrystal $11.2 Million of Cash and Cash Equivalents and Marketable Securities as of February 28, 2021

• Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

  4/12/2021

  Initial safety data expected from CAReS Study before end of 2021 Targeting multi-billion market with no approved therapies for cancer-related anorexia

• Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development

  3/19/2021

  Detection of elevated FABP5 associated with additional tumor types suggests  the target for ART26.12 may be more broadly relevant in cancer therapy Alderley Park Oncology Development Program is a UK program  designed to develop and progress innovative oncology projects

• Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd

  3/11/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, Chief Executive Officer of Artelo Biosciences, will be presenting at the Q1 Virtual Investor Summit. Event Q1 Investor Summit Date March 23-25th, 2021 Presentation March 23rd @ 1:00PM ET

• Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors

  3/9/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL ) , a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors.

• Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th

  3/2/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, Chief Executive Officer of Artelo Biosciences, will be presenting at the H.C. Wainwright Life Sciences Conference

• Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD CocrystalResearch demonstrates co-administration of CBD and TMP could confer ART12.11 with a more desirable pharmacodynamic profile

  2/17/2021

  Artelo Biosciences, Inc.  (NASDAQ:  ARTL ) today announced that Saoirse O’Sullivan, Ph.D., Professor of Pharmacology and Scientific Advisor to Artelo, along with Ryan Maguire and Dr. Timothy England of the University of Nottingham, have generated data showing potential pharmacodynamic interactions of co-administration of cannabidiol (CBD) and tetramethylpyrazine (TMP) in cell-based models of cancer.

• Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer

  2/16/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL ) , a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of Andrew Yates, Ph.D, as Senior Vice President and Chief Scientific Officer.

• Artelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants

  2/8/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the exercise of a portion of the warrants from its October 2020 financing

• Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia

  2/2/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL) today embarks on a collaboration with researchers from Trinity College Dublin to investigate pre-clinical models of human cancer cachexia, a wasting syndrome that affects up to 80% of all cancer patients and is believed to hasten death in this population.

• Artelo Biosciences to Present at the LSX World Congress Virtual Conference

  1/29/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be presenting at the LSX World Congress to be held virtually between February 1-5, 2021.

• Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update

  1/14/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today reported financial and operating results for the first quarter of its fiscal year ended November 30, 2020 and provided a business update.

• Artelo Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference

  1/5/2021

  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.